BMO-MRW best predictor of progression

Article

When detecting and evaluating the progression of glaucoma, Bruch's membrane opening-minimum rim width (BRO-MRW) may be the best predictor of the threshold of visual sensitivity and total deviation of visual field, according to a new study.

When detecting and evaluating the progression of glaucoma, Bruch's membrane opening-minimum rim width (BRO-MRW) may be the best predictor of the threshold of visual sensitivity and total deviation of visual field, according to a study published in Clinical Ophthalmology.

Japanese researchers examined the association between structural parameters of the optic nerve head and glaucomatous visual field indices in a total of 57 eyes in 33 patients with glaucomatous optic neuropathy.

The researchers measured the patients' visual fields, peripapillary retinal nerve fibre layer thickness (RNFL-T), BMO-MRW, and rim area. They then calculated Spearman's rank correlation coefficients between the threshold of visual sensitivity or total deviation of visual field and between the structural parameters as well as calculated RNFL-T and BMO-MRW volumes (each length multiplied by rim area).

They found that the threshold of visual sensitivity had the following correlation coefficients:

  • 0.23 with global sector of RNFL-T
  • 0.32 with BMO-MRW
  • 0.14 with rim area
  • 0.21 with RNFL-T volume
  • 0.26 with BMO-MRW volume

The correlation coefficients for each parameter with total deviation of visual field were as follows:

  • 0.22 with global sector of RNFL-T
  • 0.33 with BMO-MRW
  • 0.28 with rim area
  • 0.36 with RNFL-T volume
  • 0.37 with BMO-MRW volume

"Our study data confirm that total deviation was more strongly correlated with RNFL-T volume and BMO-MRW volume than with BMO-MRW. However, BMO-MRW appeared to be the best predictor of both the threshold of visual sensitivity and total deviation of visual field, and may be more useful for detecting and evaluating the progression of glaucoma," the researchers wrote.

To access the full article, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.